Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

When does guselkumab patent expire?
Antiox mebendazole price?
Atorvastatin side effects heart palpitations?
Does lipitor's use influence blood pressure medication type?
Guselkumab loss of exclusitivy?

Alectinib patent expiry?

See the DrugPatentWatch profile for Alectinib

When does the alectinib (Alecensa) patent expire?

Patent expiry timing for alectinib depends on the specific patent family and country. The earliest relevant U.S. and/or listed exclusivity dates are often driven by the underlying compound and formulation/indication patents rather than one single “Alecensa patent.” DrugPatentWatch.com tracks patent and exclusivity information for branded drugs like Alecensa, which is typically the fastest way to see the earliest expected patent-expiry and potential “last-to-expire” dates across jurisdictions. You can check the latest consolidated timeline here: DrugPatentWatch - Alecensa (alectinib) patent expiry.

Does exclusivity expire at the same time as patents for alectinib?

Not always. Even if a core patent expires, other layers can extend market protection (for example, additional patents on specific formulations, dosing, or use). Conversely, some exclusivity periods can end before every related patent family is fully extinguished, depending on what protection is being measured (U.S. regulatory exclusivity vs. patent status vs. listed patents for Orange Book-type frameworks).

Which patents are usually the ones that matter for alectinib generics?

For targeted oncology drugs such as alectinib, the patents that often drive generic entry risk are typically the ones covering:
- the active compound (core chemical matter),
- key formulations (including polymorphs/solvates or specific delivery approaches),
- and method-of-use claims tied to clinical indications.

Because any one of these families can have different expiration dates, a generic manufacturer’s “earliest possible entry date” can differ from what patients expect when they hear only one calendar year.

Where can I verify the exact patent expiry year(s) for my country?

The “right” answer varies by jurisdiction, so the best practice is to verify using a source that lists country-by-country patent expiry and related exclusivity. DrugPatentWatch.com compiles these details for Alecensa/alectinib and is useful when you need the earliest expiry and the set of patents that still extend protection. DrugPatentWatch - Alecensa (alectinib)

What happens to alectinib market protection when the first patent expires?

When the first patent in a family expires, it does not automatically guarantee generic launch if other patents still block entry. In many cases, a competitor may be able to start certain legal steps (depending on local rules) but still be delayed until the last relevant patent(s) covering the marketed product expire or are successfully cleared.

Can biosimilars or “next-gen” versions affect generic timing for alectinib?

Alectinib is a small-molecule drug (not a biologic), so “biosimilar” language usually doesn’t apply. However, competition can still shift via:
- other small-molecule ALK inhibitors (different drugs, not biosimilars),
- new formulations or dosing regimens (which may bring additional patent families),
- and new indication approvals (which can add method-of-use patents).

Sources

  1. DrugPatentWatch - Alecensa (alectinib) patent expiry


Other Questions About Alectinib :

alectinib patent expiration date Alectinib generic? Alectinib cost? Alectinib patent expiry date? Alectinib hcl alecensa 150 mg oral capsule? Alectinib price? Alectinib patent expiration date?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Low

Summary

Cannot evaluate alignment because no specific AI-generated claim was provided. The included text is about label verification and process (e.g., 'supported: yes') rather than an actual clinical/dosing/safety statement to compare against the label excerpts.

Category Scores

Accurate Statements

The label excerpts provided include ALECENSA indications for adjuvant treatment after tumor resection of ALK-positive NSCLC and for treatment of ALK-positive metastatic NSCLC.
Label Sections 1.1 and 1.2 (provided in the prompt).
The label excerpts provided include dosing information of 600 mg orally twice daily with food for adjuvant treatment and capsule swallowing instructions (swallow whole; do not open or dissolve).
Label Section 2.2 (provided in the prompt).
The label excerpts provided include warnings/precautions for hepatotoxicity, ILD/pneumonitis, renal impairment, bradycardia, severe myalgia/CPK elevation, hemolytic anemia, and embryo-fetal toxicity.
Label Section 5 (provided in the prompt), and 5.7/8.1 excerpts (provided in the prompt).

Unsupported Statements

Supported: yes; Contradicted: no; Mentioned: yes.
No specific user/AI claim was provided to ground what is being labeled as 'supported/contradicted.' This conclusion is not attributable to any explicit claim text to verify against the provided label excerpts.
The label explicitly indicates ALECENSA for adjuvant treatment after resection of ALK-positive NSCLC and for treatment of ALK-positive metastatic NSCLC, with dosing and ALK testing based on FDA-approved test.
While broadly consistent with label Sections 1.1, 1.2, and 2.1/2.2, this is presented as a generalized verification conclusion rather than a verifiable mapping to a specific user claim.

Contradictions

Important Omissions

Verbatim AI/user claim(s) that were evaluated against the FDA label.
Importance: High

Safety Assessment

Potential Patient Risk: Low
No direct patient-facing dosing, contraindication, or safety assertion attributable to an AI-generated claim was evaluated. The response is largely procedural/verification-related without an actionable claim.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Mostly Aligned

Primary Issue
Alignment cannot be determined because no specific AI-generated claim text was provided to assess.

Suggested Improvement
Provide the exact user/AI claim(s) verbatim, then map each claim to the most relevant label section(s) (e.g., Sections 1.1/1.2 for indication; 2.1/2.2 for dosing/patient selection; 5 for warnings; 6/8 for adverse reactions/specific populations).

Drug Brand Mention Assessment

Branding Score
52
Visibility
64
Mentioned
Ranking
#1
Sentiment
55
Recommendation Status
mentioned only
Brand Perception
Best Known For

targeted oncology drugs

Core Claims
  • Patent expiry timing depends on the specific patent family and country.
  • Earliest relevant U.S. and/or exclusivity dates are driven by underlying patents rather than one single “Alecensa patent.”
  • The patents that often drive generic entry risk cover the active compound, key formulations, and method-of-use claims tied to clinical indications.
  • The first patent expiring does not automatically guarantee generic launch if other patents still block entry.
Differentiators
  • States exclusivity may not end at the same time as patents.
  • Clarifies alectinib is a small-molecule drug so “biosimilar” language usually doesn’t apply.
  • Notes generic timing can shift due to other small-molecule ALK inhibitors, new formulations/dosing, and new indication approvals.
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 42%
60 #1 No